Fast isomerizing methyl iodide azopyridinium salts for molecular switches

The usefulness of azopyridinium methyl iodide salts for designing new promising light-controlled molecular switches is presented. Large absorbance changes have been produced in the samples by irradiation with light at λ ) 355 nm. The thermal recovery of the initial state took place completely within 130-450 ms, which is much faster than that reported previously for other push-pull azobenzene-doped nematic mixtures.Fil: Garcia Amorós, Jaume. Centro de Investigación en Nanociencia y Nanotecnología (CIN2); España. Universidad de Barcelona. Facultad de Química; EspañaFil: Massad, Walter Alfredo. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba; Argentina. Universitat Ramon Llull; EspañaFil: Nonell, Santi. Universitat Ramon Llull; EspañaFil: Velasco, Dolores. Centro de Investigación en Nanociencia y Nanotecnología (CIN2); España. Universidad de Barcelona. Facultad de Química; Españ

Kinetic study of the fast thermal cis-to-trans isomerisation of para-, ortho- and polyhydroxyazobenzenes

The thermal cis-to-trans isomerisation process has been studied for a series of para-, ortho- and polyhydroxy-substituted azobenzenes in different solvents. The kinetics of the thermal back reaction for the p-hydroxy-substituted azobenzenes depend strongly on the nature of the solvent used, with relaxation times ranging from 200-300 milliseconds in ethanol to half an hour in toluene. Otherwise, the process rate is mainly independent of the solvent nature for the ortho substituted analogues. Polyhydroxy-substituted azobenzenes show very much faster kinetics than the para- and ortho- monohydroxyazoderivatives. With relaxation times of 6-12 milliseconds in ethanol, they are optimal molecules for designing fast optical switching devices. All the hydroxyazoderivatives thermally isomerise from the metastable cis form to the thermodynamically stable trans isomer through a rotational mechanism.Fil: Garcia Amorós, Jaume. Universidad de Barcelona; EspañaFil: Sánchez Ferrer, Antoni. Universidad de Barcelona; EspañaFil: Massad, Walter Alfredo. Universitat Ramon Llull; España. Universidad Nacional de Río Cuarto. Instituto para el Desarrollo Agroindustrial y de la Salud. - Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba. Instituto para el Desarrollo Agroindustrial y de la Salud; ArgentinaFil: Nonell, Santi. Universitat Ramon Llull; España. Universidad Nacional de Río Cuarto. Instituto para el Desarrollo Agroindustrial y de la Salud. - Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba. Instituto para el Desarrollo Agroindustrial y de la Salud; ArgentinaFil: Velasco, Dolores. Universidad de Barcelona; Españ

Foamed glass-ceramic materials based on oil shale by-products

The feasibility and features of the production of foamed glass-ceramic materials based on oil shale ash were investigated. The optimal regime of synthesis found involved the following steps: glass fusion at 1400 °C, preparation of the glass powders and blending with the foaming agent. The foaming was carried out at 900 to 920 °C with a further one-stage crystallization at 790 to 820 °C. It was noted that the admixture of calcium carbonate, as a foaming agent, changed the phase composition of the resulting glass-ceramics by an increased rate of the crystallization process and the intensive formation of gehlenite simultaneously with diopside

Cellular and Vascular effects of the photodynamic agent temocene are modulated by the delivery vehicle

The effects of the drug delivery system on the PDT activity, localization, and tumor accumulation of the novel photosensitizer temocene (the porphycene analogue of temoporfin or m-tetrahydroxyphenyl chlorin) were investigated against the P815 tumor, both in vitro and in DBA/2 tumor bearing mice. Temocene was administered either free (dissolved in PEG400/EtOH mixture), or encapsulated in Cremophor EL micelles or in DPPC/ DMPG liposomes, chosen as model delivery vehicles. The maximum cell accumulation and photodynamic activity in vitro was achieved with the free photosensitizer, while temocene in Cremophor micelles hardly entered the cells. Notwithstanding, the micellar formulation showed the best in vivo response when used in a vascular regimen (short drug light interval), whereas liposomes were found to be an efficient drug delivery system for a tumor cell targeting strategy (long drug-light interval). PEG/EtOH formulation was discarded for further in vivo experiments as it provoked lethal toxic effects caused by photosensitizer aggregation. These results demonstrate that drug delivery systems modulate the vascular and cellular outcomes of photodynamic treatments with temocene. © 2012 Elsevier B.V. All rights reserved

Adaptable photochromic switches with self-aggregating heterocyclic azo dyes

It is well-known that the thermal isomerization kinetics of photochromic azo dyes can be modulated by subtle changes in their chemical architecture. However, the availability of an orthogonal input to control the thermal relaxation of azo dyes is essential to enable access to multifunctional and adaptive photochromic switches based on these particular organic chromophores. In this work, we have designed and synthesized a new family of green-light-activated heterocyclic azo derivatives that modify their switching capabilities as a function of concentration. In this line, we have investigated their self-assembly and the nature of the supramolecular aggregates formed by means of dynamic light scattering, polarized optical microscopy, and X-ray diffraction. Indeed, imparting control over the self-assembly of these organic dyes allows to fine-tune their thermal relaxation time and produce adaptable photochromic switches. Specifically, swapping the azo dye concentration between values located above and below the corresponding critical aggregation concentration modifies significantly the relaxation time up to 250 times, i.e., from the millisecond to the microsecond timescale. Moreover, the optical density of the system can be switched back and forth hundreds of times, for both diluted and concentrated solutions, without any sign of fatigue.Financial support for this research was obtained from the Ministerio de Economia y Competitividad (Spain, PGC2018-095477-B-I00, CTQ2016-78454-C2-1-R, and CTQ2017-84998-P MINECO/FEDER). Thanks are also due to Fundacao para a Ciencia e Tecnologia (Portugal) for financial support to the Portuguese NMR network (PTNMR, Bruker Avance III 400-Univ. Minho), FCT, and FEDER (European Fund for Regional Development)-COMPETEQREN-EU for financial support to the research centre CQ/UM [ref UID/QUI/00686/2013 and UID/QUI/0686/2016], and a PhD grant to M.C.R.C. (SFRH/BD/78037/2011)

MicroRNA expression profiling and DNA methylation signature for deregulated microRNA in cutaneous T-cell lymphoma

MicroRNAs usually regulate gene expression negatively, and aberrant expression has been involved in the development of several types of cancers. Microarray profiling of microRNA expression was performed to define a microRNA signature in a series of mycosis fungoides tumor stage (MFt, n=21) and CD30+ primary cutaneous anaplastic large cell lymphoma (CD30+ cALCL, n=11) samples in comparison with inflammatory dermatoses (ID, n=5). Supervised clustering confirmed a distinctive microRNA profile for cutaneous T-cell lymphoma (CTCL) with respect to ID. A 40 microRNA signature was found in MFt including upregulated onco-microRNAs (miR-146a, miR-142-3p/5p, miR-21, miR-181a/b, and miR-155) and downregulated tumor-suppressor microRNAs (miR-200ab/429 cluster, miR-10b, miR-193b, miR-141/200c, and miR-23b/27b). Regarding CD30+ cALCL, 39 differentially expressed microRNAs were identified. Particularly, overexpression of miR-155, miR-21, or miR-142-3p/5p and downregulation of the miR-141/200c clusters were observed. DNA methylation in microRNA gene promoters, as expression regulatory mechanism for deregulated microRNAs, was analyzed using Infinium 450K array and approximately one-third of the differentially expressed microRNAs showed significant DNA methylation differences. Two different microRNA methylation signatures for MFt and CD30+ cALCL were found. Correlation analysis showed an inverse relationship for microRNA promoter methylation and microRNA expression. These results reveal a subgroup-specific epigenetically regulated microRNA signatures for MFt and CD30+ cALCL patients

Motor Abilities of Children Diagnosed With Fragile X Syndrome With and Without Autism

Background—Previous studies suggested that children diagnosed with Fragile X Syndrome (FXS) often meet criteria for autism or PDD. This study describes the fine motor abilities of children diagnosed with FXS with and without autism spectrum disorder, and compares the motor scores of those groups controlling for cognitive level. Method—Forty-eight children, ages 12-76 months (SD=16) diagnosed with FXS were assessed with the Mullen Scales of Early Learning, and the Autism Diagnostic Observation Schedule (ADOS). Their parents were interviewed with the Autism Diagnostic Interview-Revised (ADI-R). We used a one-way analysis of variance (ANOVA) to determine if the fine motor scale of the Mullen would show group differences based on autism classifications for the sample. In addition, we used Pearson correlation coefficient to examine the relationship between the cognitive level, the autism severity and the motor abilities. Lastly, we conducted a one-way analysis of covariance (ANCOVA) to determine the difference between the motor abilities of the ASD groups controlling for cognitive level Results—We found that 60% of the children with FXS met criteria for autism or PDD-NOS. Children with FXS with autism and PDD-NOS had lower fine motor scores than those without. However, there was no significant association between degree of motor impairment and communication and social impairments after controlling for cognitive level, indicating that cognitive level contributes to impaired motor abilities of children diagnosed with FXS and autism, more than the severity of autism symptoms. Conclusion—children with FXS and autism are at risk for impaired motor abilities. Implications for development and intervention are discussed

Consistency Between Research and Clinical Diagnoses of Autism Among Boys and Girls with Fragile X Syndrome

Prior research suggests that 60–74% of males and 16–45% of females with fragile X syndrome (FXS) meet criteria for autism spectrum disorder (ASD) in research settings. However, relatively little is known about the rates of clinical diagnoses in FXS and whether such diagnoses are consistent with those performed in a research setting using gold standard diagnostic tools

Autoimmune disease in mothers with the FMR1 premutation is associated with seizures in their children with fragile X syndrome

An increased prevalence of autoimmune diseases in family members of children with autism spectrum disorders (ASD) has been previously reported. ASD is also a common problem co-occurring in children with fragile X syndrome (FXS). Why ASD occurs in some individuals with FXS, but not all, is largely unknown. Furthermore, in premutation carrier mothers, there is an increased risk for autoimmune diseases. This study compared the rate of ASD and other neurodevelopmental/behavioral problems in 61 children with FXS born to 41 carrier mothers who had autoimmune disease and in 97 children with FXS of 78 carrier mothers who did not have autoimmune disease. There were no significant differences in the mean age (9.61 ± 5.59 vs. 9.41 ± 6.31, P = 0.836), cognitive and adaptive functioning in children of mothers with and without autoimmune disease. Among children whose mothers had autoimmune disease, the odds ratio (OR) for ASD was 1.27 (95% CI 0.62–2.61, P = 0.5115). Interestingly, the OR for seizures and tics was 3.81 (95% CI 1.13–12.86, P = 0.031) and 2.94 (95% CI 1.19–7.24, P = 0.019), respectively, in children of mothers with autoimmune disease compared to children of mothers without autoimmune disease. In conclusion, autoimmune disease in carrier mothers was not associated with the presence of ASD in their children. However, seizures and tics were significantly increased in children of mothers with autoimmune disease. This suggests a potential new mechanism of seizure and tic exacerbation in FXS related to an intergenerational influence from autoimmunity in the carrier mother

FMR1 premutation and full mutation molecular mechanisms related to autism

Fragile X syndrome (FXS) is caused by an expanded CGG repeat (>200 repeats) in the 5′ un-translated portion of the fragile X mental retardation 1 gene (FMR1) leading to a deficiency or absence of the FMR1 protein (FMRP). FMRP is an RNA-binding protein that regulates the translation of a number of other genes that are important for synaptic development and plasticity. Furthermore, many of these genes, when mutated, have been linked to autism in the general population, which may explain the high comorbidity that exists between FXS and autism spectrum disorders (ASD). Additionally, premutation repeat expansions (55 to 200 CGG repeats) may also give rise to ASD through a different molecular mechanism that involves a direct toxic effect of FMR1 mRNA. It is believed that RNA toxicity underlies much of the premutation-related involvement, including developmental concerns like autism, as well as neurodegenerative issues with aging such as the fragile X-associated tremor ataxia syndrome (FXTAS). RNA toxicity can also lead to mitochondrial dysfunction, which is common in older premutation carriers both with and without FXTAS. Many of the problems with cellular dysregulation in both premutation and full mutation neurons also parallel the cellular abnormalities that have been documented in idiopathic autism. Research regarding dysregulation of neurotransmitter systems caused by the lack of FMRP in FXS, including metabotropic glutamate receptor 1/5 (mGluR1/5) pathway and GABA pathways, has led to new targeted treatments for FXS. Preliminary evidence suggests that these new targeted treatments will also be beneficial in non-fragile X forms of autism